Advances in Cancer Immunotherapy™: A Focus on MSI-High and TMB-High Cancers

Published 2/9/2022

 

Course Description

This online course includes enduring materials from the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program: A Focus on MSI-High and TMB-High Cancers. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

  PIM_logo.pngsitc_log_color.png

 

Funders Statement

The 2021–2022 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., Genentech, a Member of the Roche Group, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD), Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc.

 

Credit Available: February 9, 2022 - February 9, 2023

 

Estimated time to complete activity:  3.75 hours

 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Identify the cancer immunotherapy approaches in use for the treatment of MSI-H/TMB-H cancers.
  • Summarize recent updates in cancer immunotherapy for MSI-H/TMB-H cancers and toxicity management for key disease states.
  • Implement cancer immunotherapy for MSI-H/TMB-H cancer into clinical practice appropriately.
  • Describe the rationale for the use of cancer immunotherapy in MSI-H/TMB-H cancers.

 

Faculty

Young Kwang Chae, MD, MPH, MBA - Northwestern University

Daniel McGrail, PhD - The University of Texas MD Anderson Cancer Care Center

Zsofia Stadler, MD - Memorial Sloamn Kettering Cancer Center

John Strickler, MD - Duke University Medical Center

Nicholas DeVito, MD - Duke University Hospital

Funda Meric-Bernstam, MD - The University of Texas MD Anderson Cancer Care Center

Neil Segal, MD, PhD - Memorial Sloamn Kettering Cancer Center

Mohamed Salem, MD - Atrium Health

Theresa Brown, PharmD, BCOP - Duke University Hospital

 

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

 

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

 

Method of Participation and Request for Credit
During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 


If you wish to receive acknowledgment for completing this activity, please follow the steps indicated at the end of the course.

 

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

 

Joint Accreditation Statement

Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.  It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CME-MOC_badge.jpg

 

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 3.75 contact hours. Designated for 1.0 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

 

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hours (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-22-008-H01-P)

Type of Activity: Knowledge


Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Pre-Test
Biology Deep Dive

Meeting: 2021-2022 Advances in Cancer Immunotherapy™ - A Focus on MSI-High/TMB-High Cancers; Presenter: Nicholas DeVito, MD - Duke University Hospital; Date: November 3, 2021

TMB Current Data and Approvals

Meeting: 2021-2022 Advances in Cancer Immunotherapy™ - A Focus on MSI-High/TMB-High Cancers; Presenter: Funda Meric-Bernstam, MD - The University of Texas MD Anderson Cancer Center; Date: November 3, 2021

MSI Current Data and Approvals

Meeting: 2021-2022 Advances in Cancer Immunotherapy™ - A Focus on MSI-High/TMB-High Cancers; Presenter: Neil Segal, MD, PhD - Memoral Sloan Kettering Cancer Center; Date: November 3, 2021

The Future of MSI & TMB

Meeting: 2021-2022 Advances in Cancer Immunotherapy™ - A Focus on MSI-High/TMB-High Cancers; Presenter: Mohamed Salem, MD - Atrium Health; Date: November 3, 2021

Patient Education and Engagement in Their Treatment with Immunotherapy

Meeting: 2021-2022 Advances in Cancer Immunotherapy™ - A Focus on MSI-High/TMB-High Cancers; Presenter: Theresa S. Brown, PharmD, BCOP - Duke University Hospital; Date: November 3, 2021

Brief Primer for the Patient and Clinician on Use of NGS for Choosing Immunotherapy

Meeting: 2021-2022 Advances in Cancer Immunotherapy™ - A Focus on MSI-High/TMB-High Cancers; Presenter: Zsofia Stadler, MD - Memorial Sloan Kettering Cancer Center; Date: November 3, 2021

Debate and Faculty Panel Discussion

Meeting: 2021-2022 Advances in Cancer Immunotherapy™ - A Focus on MSI-High/TMB-High Cancers; Presenter: Young Kwang Chae, MD, MPH, MBA - Northwestern University; Daniel McGrail, PhD - The University of Texas MD Anderson Cancer Center; Zsofia Stadler, MD - Memorial Sloan Kettering Cancer Center; John Strickler, MD - Duke University Medical Center; Date: November 3, 2021

Individual topic purchase: Selected
Accreditation Council for Pharmacy Education
Contact Hour: 3.75
0.375 CEUs)
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 3.75
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 3.75
Accreditation Council for Continuing Medical Education (non-MD/DO)
AMA PRA Category 1 Credit(s)™: 3.75
Certificate of Participation (No Credit)
Certificate of Participation: 0.00
Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 3.75
Products
2021-22 Advances in Cancer Immunotherapy™ A Focus on MSI-H/TMB-H Cancers